Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ismahène Benzaïd

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Bone|December 15, 2010
Bisphosphonates in preclinical bone oncologyPhilippe Clézardin, Ismahène Benzaïd, Peter I Croucher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagementIsmahène Benzaïd, Hannu Mönkkönen, Edith Bonnelye, et al.
Cancer Research|June 8, 2011
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivoIsmahène Benzaïd, Hannu Mönkkönen, Verena Stresing, et al.
Bone|October 6, 2010
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthaseVerena Stresing, Pierrick G Fournier, Akeila Bellahcène, et al.
Science Signaling|February 14, 2019
An immunoproteomic approach to characterize the CAR interactome and signalosomeMaria C Ramello, Ismahène Benzaïd, Brent M Kuenzi, et al.
Science Advances|May 3, 2023
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancerJeremy S Frieling, Leticia Tordesillas, Xiomar E Bustos, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Bone|December 15, 2010
Bisphosphonates in preclinical bone oncologyPhilippe Clézardin, Ismahène Benzaïd, Peter I Croucher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagementIsmahène Benzaïd, Hannu Mönkkönen, Edith Bonnelye, et al.
Cancer Research|June 8, 2011
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivoIsmahène Benzaïd, Hannu Mönkkönen, Verena Stresing, et al.
Bone|October 6, 2010
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthaseVerena Stresing, Pierrick G Fournier, Akeila Bellahcène, et al.
Science Signaling|February 14, 2019
An immunoproteomic approach to characterize the CAR interactome and signalosomeMaria C Ramello, Ismahène Benzaïd, Brent M Kuenzi, et al.
Science Advances|May 3, 2023
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancerJeremy S Frieling, Leticia Tordesillas, Xiomar E Bustos, et al.
Pageof 1